Jiménez-Antón, M Dolores García-Calvo, Estefanía Gutiérrez, Cristina Escribano, Mª D Kayali, Nour Luque-García, José L Olías-Molero, Ana Isabel Corral, María J Costi, Maria P Torrado, Juan J
...
Published in
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Miltefosine is the only currently available oral drug for treatment of leishmaniasis. However, information on the pharmacokinetics (PK) of miltefosine is relatively scarce in animals. PK parameters and disposition of the molecule was determined in healthy NMRI mice and Syrian hamsters infected and treated with different miltefosine doses and regime...
Fernandez-Prada, Christopher Sharma, Mansi Plourde, Marie Bresson, Eva Roy, Gaétan Leprohon, Philippe Ouellette, Marc
Published in
International journal for parasitology. Drugs and drug resistance
Increasing drug resistance towards first line antimony-derived compounds has forced the introduction of novel therapies in leishmaniasis endemic areas including amphotericin B and miltefosine. However, their use is threatened by the emergence and spread of drug-resistant strains. In order to discover stage-dependent resistance genes, we have adapte...
Rastrojo, Alberto García-Hernández, Raquel Vargas, Paola Camacho, Esther Corvo, Laura Imamura, Hideo Dujardin, Jean-Claude Castanys, Santiago Aguado, Begoña Gamarro, Francisco
...
Published in
International journal for parasitology. Drugs and drug resistance
Leishmaniasis is a serious medical issue in many countries around the World, but it remains largely neglected in terms of research investment for developing new control and treatment measures. No vaccines exist for human use, and the chemotherapeutic agents currently used are scanty. Furthermore, for some drugs, resistance and treatment failure are...
Fragiadaki, Irene Katogiritis, Anna Calogeropoulou, Theodora Brückner, Hans Scoulica, Effie
Published in
International journal for parasitology. Drugs and drug resistance
Anti-leishmanial treatment increasingly encounters therapeutic limitations due to drug toxicity and development of resistance. The effort for new therapeutic strategies led us to work on combinations of chemically different compounds that could yield enhanced leishmanicidal effect. Peptaibols are a special type of antimicrobial peptides that are ab...
Tavassoli, Shokufeh Buckle, Miranda Tole, Derek Chiodini, Peter Darcy, Kieren
Published in
Contact lens & anterior eye : the journal of the British Contact Lens Association
Acanthamoeba keratitis (AK) is a sight threatening infection most commonly affecting contact lens wearers. The authors report a case of intractable A.polyphaga and A.castellanii, with extensive intraocular spread, managed using oral miltefosine. A 59-year old male contact lens wearer was referred to the tertiary corneal service at Bristol Eye Hospi...
Valdivieso, Elizabeth Mejías, Fabiola Torrealba, Carlos Benaim, Gustavo Kouznetsov, Vladimir V Sojo, Felipe Rojas-Ruiz, Fernando A Arvelo, Francisco Dagger, Francehuli
Published in
Acta tropica
The present study evaluates in vitro the effect of two synthetic compounds of the 7-chloro-4-aryloxyquinoline series, QI (C17H12ClNO3) and QII (C18H15ClN4O2S), on Leishmania donovani parasites. The results obtained demonstrate that these compounds are able to inhibit the proliferation of L. donovani promastigotes in a dose-dependent way (QI IC50 = ...
Sundar, Shyam Singh, Anup
Published in
Parasitology
Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging with few treatment options. Long duration of treatment and drug toxicity further limit the target of achieving VL elimination. Chemotherapy remains the treatment of choice. Single dose of liposomal amphotericin B (LAmB) and multidrug therapy (LAmB + miltefos...
Tripathi, Priyanka Jaiswal, Anil Kumar Dube, Anuradha Mishra, Prabhat Ranjan
Published in
International journal of biological macromolecules
Lipid nanoparticles are stable, biodegradable and biocompatible carriers offering excellent therapeutic efficacy. Here, a novel effort has been made to develop Miltefosine (HePC- hexadecylphosphocholine) stabilized chitosan anchored nanostructured lipid carriers (NLC) of Amphotericin B (AmB) as co-delivery vehicle to enhance killing of L. donovani....
Pandey, Rajan Kumar Kumbhar, Bajarang Vasant Srivastava, Shubham Malik, Ruchi Sundar, Shyam Kunwar, Ambarish Prajapati, Vijay Kumar
Published in
Journal of biomolecular structure & dynamics
Visceral leishmaniasis affects people from 70 countries worldwide, mostly from Indian, African and south American continent. The increasing resistance to antimonial, miltefosine and frequent toxicity of amphotericin B drives an urgent need to develop an antileishmanial drug with excellent efficacy and safety profile. In this study we have docked se...
Pandey, Rajan Kumar Kumbhar, Bajarang Vasant Sundar, Shyam Kunwar, Ambarish Prajapati, Vijay Kumar
Published in
Journal of receptor and signal transduction research
Visceral leishmaniasis (VL) is the most fatal form of leishmaniasis and it affects 70 countries worldwide. Increasing drug resistant for antileishmanial drugs such as miltefosine, sodium stibogluconate and pentamidine has been reported in the VL endemic region. Amphotericin B has shown potential antileishmanial activity in different formulations bu...
